What We're Reading: Page 169
Industry reads hand-picked by our editors
Feb 04, 2021
-
Reuters
Merck anti-baldness drug Propecia has long trail of suicide reports, records show
-
The New York Times
McKinsey Settles for $573 Million Over Role in Opioid Crisis
-
FiercePharma
Amgen cuts 'several hundred' U.S. jobs, primarily sales reps, as COVID-19 speeds a shift to digital
-
STAT
23andMe to go public via Richard Branson's SPAC
Feb 03, 2021
-
The New York Times
Study Finds AstraZeneca Shots Drastically Cut Transmission
-
FierceBioTech
Novo Nordisk's long-term chief scientific officer Thomsen retires, becomes its Foundation chief
-
In the Pipeline
Myths of Vaccine Manufacturing
-
Evaluate Vantage
Reality Bites for Amgen's bispecifics
Feb 02, 2021
Feb 01, 2021
Jan 29, 2021
-
The New York Times
Governments Sign Secret Vaccine Deals. Here’s What They Hide.
-
The Wall Street Journal
When Drug Development for Rare Disease Hit Setback, Parents Were Stung
-
Bloomberg Law
Biden Delays Drug Rebate Rule That GAO Says Violates Review Law
-
Fierce Pharma
Inside the FDA Form 483 that hurt BMS' liso-cel review
Jan 28, 2021
-
The Washington Post
Millions earmarked for public health emergencies were used to pay for unrelated projects, inspector general says
-
Evaluate Vantage
Vir becomes a biotech bubble poster child
-
The New York Times
A Scientist Is Arrested, and Academics Push Back
-
Reuters
Telehealth company Ro explores deal to go public: sources
Jan 27, 2021
-
Bloomberg
Pfizer to Deliver U.S. Covid Vaccine Doses Faster Than Expected
-
The Boston Globe
The pandemic hasn't slowed hiring at local biotech and tech companies
-
Regulatory Focus
Inspections down in 2020, but CDER hit most goal dates
-
STAT
FTC sues drug makers over allegedly illegal deal over an opioid painkiller
Previous
